Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial
Аннотация
ABSTRACT Aims To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control. Materials and Methods In this multicentre, randomised, double‐blind, placebo‐controlled Phase III trial, participants receiving metformin (≥ 1000 mg/day) plus empagliflozin 10 mg/day were randomised 1:1 to anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed‐effects model for repeated measures. Secondary endpoints included fasting plasma glucose (FPG), HbA1c target attainment, HOMA‐β and safety. Glycaemic responder analyses were conducted post hoc. Results The full analysis set included 195 participants (anagliptin, n = 97; placebo, n = 98). At Week 24, LS mean HbA1c changes were −0.81% and −0.24%, respectively, yielding a treatment difference of −0.57% (95% CI −0.74 to −0.40; p < 0.0001). FPG was also significantly reduced (between‐group difference −12.15 mg/dL, 95% CI −19.18 to −5.12; p = 0.0008). HbA1c ≤ 7.0% was achieved by 55.7% versus 25.5% of participants. HbA1c reductions ≥ 0.5% occurred in 68.0% versus 27.6%, and reductions ≥ 1.0% in 33.0% versus 9.2%. HOMA‐β improved significantly with anagliptin (between‐group difference 14.35, 95% CI 7.37–21.32; p < 0.0001). Treatment‐emergent adverse events occurred in 22.7% and 17.2%, respectively; no hypoglycaemic events or deaths were reported. Conclusions Anagliptin added to metformin and empagliflozin 10 mg provided confirmatory evidence of additional glycaemic efficacy in a separately randomised Korean population, increased glycaemic responder rates and improved estimated β‐cell function, with acceptable short‐term tolerability. Trial Registration ClinicalTrials.gov identifier: NCT05814406